shares of Karuna Therapeutics Inc (KRTX) on
Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 17 full-time employees. The firm is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. The company is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The firm is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.